ClinicalTrials.gg
RecruitingNCT04848077STEPWISEUpdated Apr 20, 2025

STEPWISE Parkinson: A Smartphone Based Exercise Solution for Patients With Parkinson's Disease

An interventional study of Step count increase with the use of a motivational smartphone application in Movement Disorders and Parkinson Disease, sponsored by Radboud University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-20.

Primary conditionParkinson DiseaseRegistry: Movement DisordersReclassifiedWhy we changed it
Registry
Movement Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Parkinson Disease
Why
  1. The study's listed conditions name Parkinson Disease, a narrower term within Movement Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Parkinson Disease by Radboud University Medical Center — 6 open to participants now, 12 under way, 1 of them phase 3. Parkinson Disease · Radboud University Medical Center.

Planned enrollment
4th of 22
452 · median 188
Started
2021
with 2 others
No phase
15 of 34
3 open now
Primary completion
2026-09
later than 6 of 11 live
Registered
17th of 34
by date

Among the 34 studies in Parkinson Disease by Radboud University Medical Center, this one is the 4th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2021, is one of 15 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 17th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 34 studies in Parkinson Disease by Radboud University Medical Center are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Parkinson Disease by Radboud University Medical Center, or all of them as a file.
02

Study summary

The aim of this study is to investigate whether a smartphone app can increase physical activity in patients with Parkinson's Disease in daily life for a long period of time (12 months).

Read the detailed description

Rationale: Exercise affords health benefits for people with Parkinson's disease (PD), but implementing exercise in daily life remains challenging. Moreover, many training programs are not very scalable. The investigators take an important step forward by developing and studying an innovative and fully decentralized smartphone-based program to increase long-term physical activity in people with PD in daily life.

Objective: The aim of this study is to investigate whether a smartphone app can increase physical activity in PD patients for a long period of time (12 months). The secondary aim is to test the potential group effect on physical fitness, motor- and non-motor symptoms. Thirdly, we aim to investigate whether there is a dose-response relationship between amount of physical activity and physical fitness, motor- and non-motor functioning.

Study design: Double-blind randomized controlled trial.

Study population: A total of 452 Dutch patients with PD who have no other medical conditions that markedly hamper mobility other than PD, no cognitive impairments that make it difficult to use a game on the smartphone and possess a suitable smartphone, will be recruited.

Intervention: Participants will be randomized to a group that will be motivated to increase their physical activity level to a small, medium, large or very large degree with respect to their own baseline level.

03

Conditions studied

  • Movement Disorders
  • Parkinson Disease

Browse trials for

Keywords

  • Physical activity
  • Walking
  • Exercise
  • Parkinson Disease
  • Locomotion
  • Motivational application
04

In context

Parkinson Disease Reclassified

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's planned enrollment of 452 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Radboud University Medical Center is the lead sponsor of 986 studies on the registry; 135 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Parkinson Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Movement Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • idiopathic PD
  • Hoehn and Yahr 1-3
  • able to understand the Dutch language
  • able to walk independently
  • equal to or less than 120 minutes of sports/outdoor activities per day (question 5-28 LASA Physical Activity Questionnaire (LAPAQ))
  • less than 7,000 steps/day during 1-month baseline (week -4 until 0)

Exclusion criteria

Exclusion Criteria:

  • weekly falls in the previous 3 months
  • medical conditions that hamper mobility other than PD
  • living in a nursing home
  • cognitive impairments that hamper use of the motivational app (subjective evaluation by the assessor)
  • not in the possession of a suitable smartphone (Iphone 5S or newer with iOS 10 or higher or Android 4.1 or newer)
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
452 participants (estimated)

Study arms

  • Experimental
    Very high dose

    Very large proportional increase in stepcount relative to baseline stepcount.

    Behavioral: Step count increase with the use of a motivational smartphone application

  • Experimental
    High dose

    Large proportional increase in stepcount relative to baseline stepcount.

    Behavioral: Step count increase with the use of a motivational smartphone application

  • Experimental
    Intermediate dose

    Medium proportional increase in stepcount relative to baseline stepcount.

    Behavioral: Step count increase with the use of a motivational smartphone application

  • Active comparator
    Active controls

    Small proportional increase in stepcount relative to baseline stepcount.

    Behavioral: Step count increase with the use of a motivational smartphone application

Interventions

  • BehavioralStep count increase with the use of a motivational smartphone application

    All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).

07

What researchers measure

Primary outcomes

  1. Mean change in step count per day

    Mean change in step count per day as measured continuously with the participant's smartphone from baseline (week -4 to 0) to follow-up (week 49-52). Higher scores indicate more physical activity (steps).

    Time frame: Week -4 until 0 and week 49 until 52

Secondary outcomes

  1. Change in physical fitness (6MWT)

    Change from baseline in meters walked during the six minute walk test (6MWT) at week 53 (follow-up). Higher scores indicate better function.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  2. Change in motor- and non-motor aspects of daily living

    Change from baseline in the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) parts Ib and II at 53 weeks (follow-up). Range 0-80. Higher scores indicate worse function.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  3. Change in physical fitness (VO2max)

    Change from baseline in VO2max in ml/kg/min assessed by a maximal aerobic exercise test on a cycle ergometer at follow-up (week 53). Higher scores indicate better function. Performed in a subgroup of 100 participants.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  4. Change in Parkinson's Disease symptoms (MDS-UPDRS)

    Change from baseline in the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) at 53 weeks (follow-up). Range 0-199. Higher scores indicate worse function. Total scores for Parts I, II, III, and IV will also be calculated.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  5. Change in ambulatory capacity (MDS-UPDRS)

    Change from baseline in the sum of 5 MDS-UPDRS questions: walking and balance \[question 2.12\], freezing \[q. 2.13\], gait \[q. 3.10\], freezing of gait \[q. 3.11\], and postural stability \[q. 3.12\]). Higher scores imply worse symptoms.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  6. Change in mobility (TUG)

    Change from baseline in the time (seconds) needed to complete the Timed Up and Go Test (TUG) at 53 weeks (follow-up). Higher scores indicate worse function.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  7. Change in balance (Mini-BestTest)

    Change from baseline on the Mini-BestTest at 53 weeks (follow-up).Range 0-28. Higher scores indicate better function.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  8. Change in gait speed (10MWT)

    Change from baseline in gait speed (m/s) as assessed by the 10 meter walk test (10MWT). Higher scores indicate better function.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  9. Change in fear of falling (FES-I)

    Change from baseline on the Dutch version of the Falls Efficacy Scale International at 53 weeks (follow-up). Range 16-64. Higher scores indicate higher fear of falling.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  10. Number of falls and near-falls (monthly fall diary)

    Number of falls and near-falls reported monthly by the participants in a fall diary drafted according to the European Physiotherapy guideline for Parkinson's Disease.

    Time frame: Every four weeks after start of the intervention (at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 weeks).

  11. Change in handgrip strength

    Change from baseline in hand grip strength (kg) as assessed with a dynamometer (best out of three attempts).

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  12. Change in self-reported physical activity level (LAPAQ)

    Change from baseline on the Longitudinal Aging Study Amsterdam (LASA) physical Activity Questionnaire (LAPAQ). Higher scores indicate a higher physical activity level.

    Time frame: Week -4 (screening), week 0 (baseline) and week 53 (follow-up)

  13. Change in cognition (MOCA)

    Change from baseline on the Montreal Cognitive Assessement (MOCA) score at 53 weeks (follow-up). Range 0-30. Higher scores indicate better cognition.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  14. Change in depression and anxiety (HADS)

    Change from baseline on the Hospital Anxiety and Depression Scale (HADS) at 53 weeks (follow-up). Range 0-42. Higher scores indicate worse function.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  15. Change in apathy (AES-12PD)

    Change from baseline on the Apathy Evaluation Scale (AES-12PD) at 53 weeks (follow-up). Range 12-48. Higher scores indicate better function.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  16. Change in fatigue (FSS)

    Change from baseline on the Fatigue Severity Scale (FSS) at 53 weeks (follow-up). Range 1-7. Higher scores indicate worse function.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  17. Change in severity of sleep problems and daytime sleepiness (SCOPA-SLEEP)

    Change from baseline on the Scales for Outcomes in Parkinson's Disease - Sleep (SCOPA-Sleep) questionnaire at 53 weeks (follow-up).

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  18. Change in autonomic dysfunction (SCOPA-AUT)

    Change from baseline on the Scales for Outcomes in Parkinson's Disease - autonomic questionnaire (SCOPA-AUT) at 53 weeks (follow-up).

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  19. Change in Health related quality of life (PDQ-39)

    Change from baseline on the Health related quality of life (PDQ-39) questionnaire at 53 weeks (follow-up). Range 0-100. Higher scores indicate better function.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  20. Perceived effect of intervention (GPE)

    Perceived effect of intervention as assessed by the Global Perceived effect (GPE) questionnaire (7-point scale) at 53 weeks (follow-up). Range 1-7. Higher scores indicate higher perceived effect.

    Time frame: At week 53 (follow-up)

  21. System Usability (SUS)

    Usability of the STEPWISE application as assessed by the Dutch version of the System Usability Scale (SUS) at 53 weeks (follow-up). Range 0-100. Higher scores indicate better usability.

    Time frame: At week 53 (follow-up)

  22. Perceived physical ability (LIVAS)

    Change from baseline on the percieved physical ability scale (Lichamelijke Vaardigheden Schaal; LIVAS) at 53 weeks (follow-up). Range 10-50. Higher scores indicate higher perceived phisical ability.

    Time frame: Week 0 (baseline) and week 53 (follow-up)

Other outcomes

  1. STEPWISE Parkinson smartphone application data

    User data from the STEPWISE smartphone application will be collected, including number of interactions with the app and the total time the application was used.

    Time frame: From baseline (week 0) to follow-up (week 53)

  2. Adherence to the intervention

    Adherence to the study intervention as indicated by the number of days the STEPWISE app was used.

    Time frame: From baseline (week 0) to follow-up (week 53)

  3. Barriers and motivators to engage in exercise/physical activity at baseline and follow-up

    Barriers and motivators to engage in exercise/physical activity reported on the self-developed Barriers and Motivators questionnaire at week 0 (baseline) and week 53 (follow-up).

    Time frame: Week 0 (baseline) and week 53 (follow-up)

  4. Exploratory measurement of physical acitivity with wearable sensor

    Movement data captured with a 6-axis inertial movement sensor (Axivity AX6).

    Time frame: From week 0 (baseline) to week 1 and from week 52 to week 53 (follow-up)

  5. Parkinson's disease symptoms monitored with the mPower app

    Parkinson's disease symptoms monitored remotely with the mPower smartphone app.

    Time frame: Every three months from week 0 (baseline) to week 53 (follow-up)

  6. Blood-based biomarkers

    Change in blood-based biomarkers. Assays will be determined before unblinding. Collected for a subgroup of participants (maximum n=135).

    Time frame: Week 0 (baseline) and week 53 (follow-up)

08

Study locations

1 of 1 sites recruiting
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We will make relevant and anonymised data available in a validated database.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After publication of the main results of our trial.

Access criteria: Access to the data is restricted, meaning that researchers who are interested in re-use of the data are asked to contact the central contact person for permission. Approval is given after a signed agreement.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Sep 2026, 64 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 64 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2021
First posted
Apr 19, 2021
StartActual
May 18, 2021
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Apr 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04848077
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Massachusetts General Hospital, Hogeschool van Arnhem en Nijmegen (HAN), Canisius-Wilhelmina Hospital, IJsfontein Health BV
Responsible party
Sponsor
First posted
Apr 19, 2021
Start date
May 18, 2021
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Apr 20, 2025

Study contacts

Sabine Schootemeijer, MSc
Contact
sabine.schootemeijer@radboudumc.nl
00316 50155754
Bastiaan Bloem, Prof. Dr.
principal investigator · Radboudumc Department of Neurology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion